TIDMSNG
RNS Number : 5946P
Synairgen plc
20 October 2021
Synairgen plc
('Synairgen' or the 'Company')
Synairgen announces its inhaled interferon beta (SNG001) is
advancing to Phase 3 of the NIH-sponsored
ACTIV-2 COVID-19 Trial
Southampton, UK - 20 October 2021: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, a formulation for inhalation
containing the broad-spectrum anti-viral protein interferon beta
(IFN-beta) for the treatment of severe viral lung infections, has
been informed that the external data safety monitoring board (DSMB)
of the ACTIV-2 study has recommended that SNG001 advance into Phase
3 in mild to moderate COVID-19 patients.
Phillip Monk, Chief Scientific Officer of Synairgen, explained :
"Interferon beta is a naturally-occurring protein, which
orchestrates the body's antiviral responses. SARS-CoV-2 suppresses
IFN-beta production to compromise the immune system; the aim of
delivering SNG001 directly into the lungs is to restore or boost
natural antiviral defences to prevent the virus from causing severe
lower respiratory tract illness. Unfortunately, despite vaccination
programmes and early interventions, thousands of patients are still
hospitalised every day due to COVID-19-induced breathing
difficulties. Data to date suggests SNG001 is well tolerated with a
favourable safety profile and there is growing evidence to support
the rationale for delivering IFN-beta directly into the lungs to
counter the effects of SARS-CoV-2."
Richard Marsden, CEO of Synairgen, said: "The advancement of
SNG001 from Phase 2 to Phase 3 of the large ACTIV-2 trial is very
welcome news and continues to build the case that our formulation
of inhaled IFN-beta may have an important role in combatting
COVID-19 and future emerging virus threats. In addition to the
ACTIV-2 trial, our own Phase III SPRINTER study assessing SNG001 in
hospitalised COVID-19 patients, is also progressing well and we
expect top-line results in early 2022."
As of today, Synairgen has not received any data from the
ACTIV-2 trial.
Accelerating COVID-19 Therapeutic Interventions and Vaccines
(ACTIV) is a public-private partnership to develop a coordinated
research strategy to accelerate the development of the most
promising COVID-19 treatments and vaccines. ACTIV-2 is testing
agents in non-hospitalised adults experiencing mild to moderate
COVID-19 and is sponsored by NIAID, part of the National Institutes
of Health, and is led by the NIAID-funded AIDS Clinical Trials
Group (ACTG). To read more about ACTIV-2, visit their website here
.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No. 596/2014 ('MAR').
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Brooke.Clarke@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs. Granted Fast Track status from the US Food and Drug
Administration (FDA) and deemed an Urgent Public Health study by
the UK's National Institute for Health Research (NIHR), Synairgen's
Phase III clinical programme is currently evaluating nebulised
SNG001 in patients across 17 countries. In a Phase II trial in
hospitalised COVID-19 patients, SNG001 demonstrated a greater than
two-fold chance of recovery to 'no limitation of activities' versus
placebo.(1)
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
1 -
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPGUCUUPGPGB
(END) Dow Jones Newswires
October 20, 2021 02:00 ET (06:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024